Polymorphisms in the BER and NER pathways and their influence on survival and toxicity in never-smokers with lung cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 12 2020
03 12 2020
Historique:
received:
26
08
2020
accepted:
11
11
2020
entrez:
4
12
2020
pubmed:
5
12
2020
medline:
2
4
2021
Statut:
epublish
Résumé
Polymorphisms in DNA repair pathways may play a relevant role in lung cancer survival in never-smokers. Furthermore, they could be implicated in the response to chemotherapy and toxicity of platinum agents. The aim of this study was to evaluate the influence of various genetic polymorphisms in the BER and NER DNA repair pathways on survival and toxicity in never-smoker LC patients. The study included never-smokers LC cases diagnosed from 2011 through 2019, belonging to the Lung Cancer Research In Never Smokers study. A total of 356 never-smokers cases participated (79% women; 83% adenocarcinoma and 65% stage IV). Survival at 3 and 5 years from diagnosis was not associated with genetic polymorphisms, except in the subgroup of patients who received radiotherapy or chemo-radiotherapy, and presented with ERCC1 rs3212986 polymorphism. There was greater toxicity in those presenting OGG1 rs1052133 (CG) and ERCC1 rs11615 polymorphisms among patients treated with radiotherapy or chemo-radiotherapy, respectively. In general, polymorphisms in the BER and NER pathways do not seem to play a relevant role in survival and response to treatment among never-smoker LC patients.
Identifiants
pubmed: 33273562
doi: 10.1038/s41598-020-78051-5
pii: 10.1038/s41598-020-78051-5
pmc: PMC7713126
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
21147Références
Int J Biochem Cell Biol. 2007;39(7-8):1318-28
pubmed: 17600754
Pharmacogenomics. 2012 Jul;13(9):1073-86
pubmed: 22838953
Onco Targets Ther. 2016 Sep 16;9:5693-5698
pubmed: 27695347
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Asian Pac J Cancer Prev. 2012;13(6):2583-6
pubmed: 22938424
Tumori. 2017 Jul 31;103(4):338-344
pubmed: 28315511
Cancer Lett. 2019 Jun 1;451:142-149
pubmed: 30851418
PLoS One. 2015 Apr 13;10(4):e0118660
pubmed: 25867025
J Clin Oncol. 2006 Apr 10;24(11):1761-9
pubmed: 16603718
Cancer Lett. 2014 Oct 28;353(2):160-6
pubmed: 25069034
Lung Cancer. 2012 Jan;75(1):102-9
pubmed: 21676483
Anticancer Res. 2004 Jan-Feb;24(1):241-7
pubmed: 15015603
J Cell Biochem. 2017 Dec;118(12):4782-4791
pubmed: 28520216
Environ Res. 2019 May;172:713-718
pubmed: 30903971
Cancer Epidemiol Biomarkers Prev. 2012 Jun;21(6):951-8
pubmed: 22539606
N Engl J Med. 2002 Jan 10;346(2):92-8
pubmed: 11784875
Cancer Treat Rev. 1998 Oct;24(5):331-44
pubmed: 9861196
Cancer. 2012 May 1;118(9):2466-75
pubmed: 22031394
J Thorac Oncol. 2014 Aug;9(8):1073-80
pubmed: 24852519
Asian Pac J Cancer Prev. 2013;14(1):145-8
pubmed: 23534713
Clin Lung Cancer. 2009 Mar;10(2):118-23
pubmed: 19362955
J Thorac Oncol. 2015 Sep;10(9):1279-1284
pubmed: 26287318
Philos Trans R Soc Lond B Biol Sci. 1995 Jan 30;347(1319):63-8
pubmed: 7746856
J Thorac Oncol. 2011 Dec;6(12):2018-26
pubmed: 22052224
Lung Cancer. 2010 Jan;67(1):101-7
pubmed: 19361884
Lung Cancer. 2002 Mar;35(3):221-9
pubmed: 11844594
IARC Sci Publ. 1999;(148):231-49
pubmed: 10493261
N Engl J Med. 2008 Sep 25;359(13):1367-80
pubmed: 18815398
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Clin Cancer Res. 2008 Mar 1;14(5):1291-5
pubmed: 18316546
Respir Med. 2012 Sep;106(9):1301-8
pubmed: 22749756
Exp Mol Med. 2003 Apr 30;35(2):106-12
pubmed: 12754414